Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects

British Journal of Clinical Pharmacology

Volumn 43, Issue 6, 1997, Pages 571-578

  Aoyama, K ^a   Uchida, T ^a   Takanuki, F ^a   Usui, T ^a   Watanabe, T ^a   Higuchi, S ^a   Toyoki, T ^b   Mizoguchi, H ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b Kan nondai Clinic   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Bioavailability; ELISA; Intravenous; Pharmacokinetics; Recombinant human interleukin 11; Subcutaneous

Indexed keywords

RECOMBINANT INTERLEUKIN 11;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030788282     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00605.x     Document Type: Article

References (20)

1. Paul SR, Bennet F, Calvetti JA, et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990; 87: 7512-7516.
2. Yonemura Y, Kawakita M, Masuda T, Fujimoto K, Kato K, Takatsuki K. Synergistic effect of interleukin 3 and interleukin 11 on murine megakaryopoiesis in serum-free culture. Exp Hematol 1992; 20: 1011-1016.
3. Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H. Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 1992; 79: 327-331.
4. Neben TY, Loebelenz J, Hayes L, et al. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 1993; 81: 901-908.
5. Leonard JP, Quinto CM, Kozitza MK, Neben TY, Goldman SJ. Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. Blood 1994; 83: 1499-1506.
6. Gordon MS, Sledge Jr GW, Battiato L, et al. The in vivo effects of subcutaneously administered recombinant human interleukin-11 in women with breast cancer. Blood 1993; 82 Suppl.: 1976.
7. Gordon MS, Battiato L, Hoffman R, et al. Subcutaneously administered recombinant human interleukin-11 prevents thrombocytopenia following chemotherapy with cyclophosphamide and doxorubicin in women with breast cancer. Blood 1993; 82 Suppl.: 1258.
8. Gibaldi M. Noncompartmental pharmacokinetics. In Biopharmaceutics and Clinical Pharmacokinetics, Third Edition, Philadelphia: Lea & Febiger, 1984: 17-28.
9. Hori R, He YL, Shima T, et al. Total body and hepatic clearance in rats of recombinant tissue-type plasminogen activator expressed in mouse C127 and chinese hamster ovary cells. Drug Metab Dispos 1992; 20: 541-546.
10. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992; 81: 309-312.
11. Supersaxo A, Hein WR, Stefan H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following s.c. administration. Pharm Res 1990; 7: 167-169.
12. Huhn RD, Yurkow EJ, Kuhn JG, et al. Pharmacodynamics of daily s.c. recombinant human interleukin-3 in normal volunteers. Clin Pharmacol Ther 1995; 57: 32-41.
13. Petros WP, Rabinowitz J, Stuart AR, et al. Disposition of recombinant human Granulocyte-Macrophage Colony-Stimulating Factor in patients receiving high-dose chemotherapy and autologous bone marrow support. Blood 1992; 80: 1135-1140.
14. Levinson SS. The nature of heterophilic antibodies and their role in immunoassay interference. J Clin Immunoassay 1992; 15: 108-115.
15. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review. Kidney Int 1979; 16: 251-270.
16. Bocci V. Catabolism of therapeutic proteins and peptides with implications for drug delivery. Adv Drug Deliv Rev 1990; 4: 149-169.
17. Gibbons JA, Luo ZP, Hannon ER, Braeckman RA, Young JD. Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureter-ligated rats. J Pharmacol Exp Ther 1995; 272: 119-125.
18. Ohnishi H, Chao JTY, Lin KKM, Lee H, Chu TM. Role of the kidney in metabolic change of interleukin-2. Tumor Biol 1989; 10: 202-214.
19. Ohnishi H, Lin KM, Chu TM. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. Cancer Res 1990; 50: 1107-1112.
20. Takagi A, Masuda H, Takakura Y, Hashida M. Disposition characteristics of recombinant human interleukin-11 after a bolus i.v. administration in mice. J Pharmacol Exp Ther 1995; 275: 537-543.